Toxicological Profiling of Engineered Nanomaterials (ENMs) in the MPS (RES)
MPS (RES) 中工程纳米材料 (ENM) 的毒理学分析
基本信息
- 批准号:9186735
- 负责人:
- 金额:$ 41.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-01 至 2021-08-31
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAcuteAddressAdoptive TransferAnimalsAntigensAutophagocytosisBiochemicalBiocompatible Coated MaterialsBiodistributionBiological PreservationBlood CirculationCategoriesCell membraneCell physiologyCellsCellular StructuresChronicCoculture TechniquesCollaborationsDataDecision AnalysisDecision MakingDendritic CellsDevelopmentDiseaseEngineeringExposure toGoalsHazard AssessmentHazardous SubstancesHepatocyteHepatotoxicityHumanImageImmune systemIn VitroInflammationInjection of therapeutic agentInjuryIntravenousKnowledgeKupffer CellsLibrariesLinkLiverLungMediatingMethodsMissionModelingMolecularMononuclearMusOrganOutcomeOxidation-ReductionOxidative StressPathway interactionsPeptidesPhagocytesPharmaceutical PreparationsPhysiologicalPropertyPublic HealthReporter GenesResearchResearch PersonnelReticuloendothelial SystemRiskRisk AssessmentSafetyShapesSkinStructure-Activity RelationshipSurfaceSystemT-LymphocyteTestingTherapeuticTissuesToxic effectToxicity TestsTransgenic AnimalsWorkadverse outcomeanimal tissueantigen challengebasebody systemcombinatorialdesigndisabilityexperiencehazardimmunotoxicityin vivoinnovationmacrophagenanonanomaterialsnanoparticlenew technologynovelpredictive modelingprotective effectresponsescreening
项目摘要
Project Summary
There is a fundamental gap in understanding the impact of engineered nanomaterials (ENM) on the
mononuclear phagocyte system (MPS), including Kupffer cells (KC) in the liver and antigen-presenting
dendritic cells (DC) in the immune system. Our long-term goal is to develop a predictive 21st century
toxicological platform for ENM safety assessment that is premised on cellular and organotypic cultures for high
content screening, in which we will use adverse outcome pathways (AOPs) to derive structure-activity
relationships (SARs) for toxicological profiling and decision analysis on consortium-provided ENMs. The
overall objective is to use our mechanistic and high content screening approaches to perform hazard ranking,
tiered risk assessment, and SAR analysis that link ENM physicochemical properties to AOPs in KC and DC,
which is then used as the basis of in vivo predictions of the adverse impact on the liver and immune system.
Our central hypothesis is that linkage of the ENM properties to molecular and pathophysiological alterations in
the MPS will allow a mechanistic and high throughput approach for predicting the hazardous impact of ENMs
on the MPS. The rationale of the proposed research is that the development of predictive and alternative
testing platforms, including organotypic and cell co-culture models, will allow expedited risk assessment and
categorization of broad ENM categories. Guided by our extensive experience for predictive toxicological
modeling, we propose to explore the impact of the consortium-provided ENMs on the MPS in three specific
aims: Aim 1: To use mechanistic, high content screening for hazard ranking and toxicological profiling of a
diverse range of ENMs in KC and DC for SAR analysis and predictive toxicological profiling that can be used to
plan studies in liver micro-tissues and animals. Aim 2: To use organotypic 3-D liver models, and limited in vivo
toxicity assessment, imaging and biodistribution studies for toxicological profiling of a diverse range of related
to toxicological injury pathways at the KC/hepatocyte interface and the liver of transgenic animals that express
reporter genes (e.g., NF-κB). Aim 3: To use an antigen-specific (OVA peptide) dendritic and T-cell co-culture
system and adoptive transfer in mice for toxicological and immunotoxicological profiling of a diverse range of
ENMs, prior screened in Aim 1. Our approach is innovative, because of the substantive departure from the
current status quo, where descriptive single agent toxicity testing will be replaced by rapid throughput, high
content, and AOP-based predictive toxicological approaches for ENM effects on the MPS. The proposed
research is significant because we will introduce mechanisms-based HTS approaches that can be used to link
ENMs physicochemical properties to cellular and molecular response profiles for hazard profiling of
intravenous injected ENMs. Not only will this provide a platform for expedited safety assessment of ENMs, but
will also form the basis of extensive collaboration with the consortium, where predictive modeling can be used
to study exposure systems such as the lung, GIT and the skin.
项目摘要
在理解工程纳米材料(ENM)对环境的影响方面存在根本性的差距。
单核吞噬细胞系统(MPS),包括肝脏中的枯否细胞(KC)和抗原呈递细胞
树突状细胞(DC)在免疫系统中的作用。我们的长期目标是开发一个可预测的世纪
用于ENM安全性评估的毒理学平台,该平台基于细胞和器官型培养物,
内容筛选,其中我们将使用不良结果途径(AOP)来推导结构-活性
对联合体提供的ENM进行毒理学分析和决策分析的SAR。的
总体目标是使用我们的机械和高内容筛选方法来执行危害排序,
分层风险评估和SAR分析,将ENM理化性质与KC和DC中的AOP联系起来,
然后将其用作对肝脏和免疫系统的不利影响的体内预测的基础。
我们的中心假设是ENM特性与细胞内分子和病理生理学改变的联系。
MPS将允许一种机械的、高通量的方法来预测电磁导弹的危险影响
关于MPS拟议研究的基本原理是,预测和替代的发展
测试平台,包括器官型和细胞共培养模型,将允许加速风险评估,
广泛的ENM类别的分类。我们在预测毒理学方面的丰富经验
通过建模,我们建议在三个具体的方面探索财团提供的ENM对MPS的影响
目的:目的1:使用机械的、高含量的筛选方法对一种有毒物质进行危害排序和毒理学特征分析。
KC和DC中用于SAR分析和预测毒理学分析的各种ENM,可用于
计划在肝脏微组织和动物中进行研究。目的2:建立器官型三维肝脏模型,并在活体内进行限制性研究
毒性评估、成像和生物分布研究,用于各种相关的
在KC/肝细胞界面和表达的转基因动物的肝脏的毒理学损伤途径,
报告基因(例如,NF-κB)。目的3:使用抗原特异性(OVA肽)树突状细胞和T细胞共培养物
系统和过继性转移,用于多种
ENM,目标1中预先筛选。我们的做法是创新的,因为我们从实质上背离了
目前的现状是,描述性单一药剂毒性测试将被快速通量取代,
内容,和AOP为基础的预测毒理学方法ENM对MPS的影响。拟议
研究是重要的,因为我们将介绍基于机制的高温超导方法,可以用来连接
ENM的理化特性对细胞和分子响应谱的影响,
静脉注射ENMs。这不仅将为加速ENM的安全性评估提供平台,
还将形成与该联盟广泛合作的基础,在该联盟中可以使用预测建模
研究暴露系统,如肺,GIT和皮肤。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andre Elias Nel其他文献
Andre Elias Nel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andre Elias Nel', 18)}}的其他基金
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
使用纳米平台进行胰腺癌免疫治疗
- 批准号:
10187533 - 财政年份:2020
- 资助金额:
$ 41.8万 - 项目类别:
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
使用纳米平台进行胰腺癌免疫治疗
- 批准号:
10058189 - 财政年份:2020
- 资助金额:
$ 41.8万 - 项目类别:
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
使用纳米平台进行胰腺癌免疫治疗
- 批准号:
10417161 - 财政年份:2020
- 资助金额:
$ 41.8万 - 项目类别:
Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy
使用纳米平台进行胰腺癌免疫治疗
- 批准号:
10654816 - 财政年份:2020
- 资助金额:
$ 41.8万 - 项目类别:
Toxicological Profiling of Engineered Nanomaterials (ENMs) in the MPS (RES)
MPS (RES) 中工程纳米材料 (ENM) 的毒理学分析
- 批准号:
9341321 - 财政年份:2016
- 资助金额:
$ 41.8万 - 项目类别:
Toxicological Profiling of Engineered Nanomaterials (ENMs) in the MPS (RES)
MPS (RES) 中工程纳米材料 (ENM) 的毒理学分析
- 批准号:
9769728 - 财政年份:2016
- 资助金额:
$ 41.8万 - 项目类别:
Nanovalve Platform: Targeted, Controlled, Release of Anticancer Drugs
Nanovalve平台:靶向、可控、释放抗癌药物
- 批准号:
8206804 - 财政年份:2010
- 资助金额:
$ 41.8万 - 项目类别:
Center for Nanobiology and Predictive Toxicology
纳米生物学和预测毒理学中心
- 批准号:
8464703 - 财政年份:2010
- 资助金额:
$ 41.8万 - 项目类别:
Center for Nanobiology and Predictive Toxicology
纳米生物学和预测毒理学中心
- 批准号:
8393965 - 财政年份:2010
- 资助金额:
$ 41.8万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 41.8万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 41.8万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 41.8万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 41.8万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 41.8万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 41.8万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 41.8万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 41.8万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 41.8万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 41.8万 - 项目类别:
Operating Grants